FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221008799> ?p ?o ?g. }

• W4221008799 abstract "To explore whether the rectal distension-mediated technique, harnessing human physiology to achieve intrafractional prostate motion mitigation, enables urethra sparing by inverse dose painting, thus promoting dose escalation with extreme hypofractionated stereotactic ablative radiotherapy (SABR) in prostate cancer.Between June 2013 and December 2018, 444 patients received 5 × 9 Gy SABR over 5 consecutive days. Rectal distension-mediated SABR was employed via insertion of a 150-cm3 air-inflated endorectal balloon. A Foley catheter loaded with 3 beacon transponders was used for urethra visualization and online tracking. MRI-based planning using Volumetric Modulated Arc Therapy - Image Guided Radiotherapy (VMAT-IGRT) with inverse dose painting was employed in delivering the planning target volume (PTV) dose and in sculpting exposure of organs at risk (OARs). A 2-mm margin was used for PTV expansion, reduced to 0 mm at the interface with critical OARs. All plans fulfilled Dmean ≥45 Gy. Target motion ≥2 mm/5 s motions mandated treatment interruption and target realignment prior to completion of the planned dose delivery.Patient compliance to the rectal distension-mediated immobilization protocol was excellent, achieving reproducible daily prostate localization at a patient-specific retropubic niche. Online tracking recorded ≤1-mm intrafractional target deviations in 95% of treatment sessions, while target realignment in ≥2-mm deviations enabled treatment completion as scheduled in all cases. The cumulative incidence rates of late grade ≥2 genitourinary (GU) and gastrointestinal (GI) toxicities were 5.3% and 1.1%, respectively. The favorable toxicity profile was corroborated by patient-reported quality of life (QOL) outcomes. Median prostate-specific antigen (PSA) nadir by 5 years was 0.19 ng/ml. The cumulative incidence rate of biochemical failure using the Phoenix definition was 2%, 16.6%, and 27.2% for the combined low/favorable-intermediate, unfavorable intermediate, and high-risk categories, respectively. Patients with a PSA failure underwent a 68Ga-labeled prostate-specific membrane antigen (68Ga-PSMA) scan showing a 20.2% cumulative incidence of intraprostatic relapses in biopsy International Society of Urological Pathology (ISUP) grade ≥3.The rectal distension-mediated technique is feasible and well tolerated. Dose escalation to 45 Gy with urethra-sparing results in excellent toxicity profiles and PSA relapse rates similar to those reported by other dose-escalated regimens. The existence of intraprostatic recurrences in patients with high-risk features confirms the notion of a high α/β ratio in these phenotypes resulting in diminished effectiveness with hypofractionated dose escalation." @default.
• W4221008799 created "2022-04-03" @default.
• W4221008799 creator A5005999785 @default.
• W4221008799 creator A5014217525 @default.
• W4221008799 creator A5017722963 @default.
• W4221008799 creator A5018175237 @default.
• W4221008799 creator A5018489699 @default.
• W4221008799 creator A5023269901 @default.
• W4221008799 creator A5031115939 @default.
• W4221008799 creator A5038678908 @default.
• W4221008799 creator A5045507574 @default.
• W4221008799 creator A5049374416 @default.
• W4221008799 creator A5051424316 @default.
• W4221008799 creator A5058533144 @default.
• W4221008799 creator A5066778914 @default.
• W4221008799 creator A5080794141 @default.
• W4221008799 creator A5088763363 @default.
• W4221008799 date "2022-03-29" @default.
• W4221008799 modified "2023-10-14" @default.
• W4221008799 title "Urethra Sparing With Target Motion Mitigation in Dose-Escalated Extreme Hypofractionated Prostate Cancer Radiotherapy: 7-Year Results From a Phase II Study" @default.
• W4221008799 cites W1500625567 @default.
• W4221008799 cites W1967227522 @default.
• W4221008799 cites W1977694951 @default.
• W4221008799 cites W1982410442 @default.
• W4221008799 cites W1983228790 @default.
• W4221008799 cites W1986019734 @default.
• W4221008799 cites W1986583589 @default.
• W4221008799 cites W1987258773 @default.
• W4221008799 cites W1987470170 @default.
• W4221008799 cites W1991048589 @default.
• W4221008799 cites W1992542077 @default.
• W4221008799 cites W2001253798 @default.
• W4221008799 cites W2019819653 @default.
• W4221008799 cites W2060794568 @default.
• W4221008799 cites W2076854628 @default.
• W4221008799 cites W2079190531 @default.
• W4221008799 cites W2081224511 @default.
• W4221008799 cites W2094442174 @default.
• W4221008799 cites W2099589368 @default.
• W4221008799 cites W2104623412 @default.
• W4221008799 cites W2104631398 @default.
• W4221008799 cites W2117559428 @default.
• W4221008799 cites W2123217416 @default.
• W4221008799 cites W2125346579 @default.
• W4221008799 cites W2130262490 @default.
• W4221008799 cites W2153674426 @default.
• W4221008799 cites W2160109879 @default.
• W4221008799 cites W2162439557 @default.
• W4221008799 cites W2205578143 @default.
• W4221008799 cites W2285465212 @default.
• W4221008799 cites W2320858353 @default.
• W4221008799 cites W2337386322 @default.
• W4221008799 cites W2465092116 @default.
• W4221008799 cites W2469323349 @default.
• W4221008799 cites W2488360120 @default.
• W4221008799 cites W2523547317 @default.
• W4221008799 cites W2560303100 @default.
• W4221008799 cites W2603384438 @default.
• W4221008799 cites W2605811459 @default.
• W4221008799 cites W2759104970 @default.
• W4221008799 cites W2768699815 @default.
• W4221008799 cites W2772705486 @default.
• W4221008799 cites W2791440729 @default.
• W4221008799 cites W2799363517 @default.
• W4221008799 cites W2799493455 @default.
• W4221008799 cites W2800183199 @default.
• W4221008799 cites W2828561204 @default.
• W4221008799 cites W2858687552 @default.
• W4221008799 cites W2914880936 @default.
• W4221008799 cites W2922688802 @default.
• W4221008799 cites W2928985222 @default.
• W4221008799 cites W2969176485 @default.
• W4221008799 cites W2981543031 @default.
• W4221008799 cites W3002858853 @default.
• W4221008799 cites W3008246956 @default.
• W4221008799 cites W3011586574 @default.
• W4221008799 cites W3091776643 @default.
• W4221008799 cites W3096454384 @default.
• W4221008799 cites W3113223508 @default.
• W4221008799 cites W3118166616 @default.
• W4221008799 cites W3125222626 @default.
• W4221008799 cites W3129679350 @default.
• W4221008799 cites W3133698264 @default.
• W4221008799 cites W3137534101 @default.
• W4221008799 cites W3161299826 @default.
• W4221008799 cites W3189200584 @default.
• W4221008799 cites W3202899348 @default.
• W4221008799 cites W3209108213 @default.
• W4221008799 cites W3216111656 @default.
• W4221008799 cites W4292929888 @default.
• W4221008799 cites W92155372 @default.
• W4221008799 doi "https://doi.org/10.3389/fonc.2022.863655" @default.
• W4221008799 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35433469" @default.
• W4221008799 hasPublicationYear "2022" @default.
• W4221008799 type Work @default.
• W4221008799 citedByCount "3" @default.
• W4221008799 countsByYear W42210087992022 @default.
• W4221008799 countsByYear W42210087992023 @default.
• W4221008799 crossrefType "journal-article" @default.
• W4221008799 hasAuthorship W4221008799A5005999785 @default.

• next